TY - JOUR
T1 - Efficacy of Oral Nifedipine, Naproxen, or Placebo for Pain Relief During Diagnostic Hysteroscopy in an Office Setting
T2 - A Randomized Pilot Study
AU - van Wessel, Steffi
AU - Rombaut, Julie
AU - Vanhulle, Astrid
AU - Emanuel, Mark Hans
AU - Hamerlynck, Tjalina
AU - Weyers, Steven
N1 - Publisher Copyright:
© 2023 AAGL
PY - 2023/6
Y1 - 2023/6
N2 - Study Objective: To compare nifedipine, naproxen, or placebo for pain relief during diagnostic hysteroscopy. Design: Double-blind, randomized controlled pilot study. Setting: University hospital. Patients: Women scheduled for office diagnostic hysteroscopy (n = 60). Interventions: Women received nifedipine (2 tablets of 10 mg), naproxen (2 tablets of 250 mg), or placebo (2 tablets of 500 mg lactose) 30 to 60 minutes prior to hysteroscopy. Measurements and Main Results: Sixty patients were enrolled in the study (21 in the nifedipine group, 19 in the naproxen group, and 20 in the placebo group). The median pain scores during hysteroscope insertion, measured on a Visual Analog Scale (VAS), were 1 (interquartile range (IQR) 0–0), 2 (0–4) and 1 (0–1) in the nifedipine, naproxen and placebo group, respectively (P,14). The median VAS scores during hysteroscopy were 5 (IQR 2–7), 5 (4–8) and 5 (3–7) in the nifedipine, naproxen and placebo group, respectively (P,73). The median VAS scores immediately after hysteroscopy were 2 (IQR 0–4), 3 (0–6) and 3 (1–5) in the nifedipine, naproxen and placebo group, respectively (P,40). The median VAS scores 30 minutes after hysteroscopy were 1 (IQR 0–2), 1 (0–1) and 1 (0–2) in the nifedipine, naproxen and placebo group, respectively (P,63). Hysteroscope insertion failed in 1 case (naproxen group) because of cervica`l stenosis (P,32). Flushes, fatigue and vertigo, 30 minutes after the procedure, were significantly more prevalent in the nifedipine group compared to the naproxen (p < .001, p,03, p,03, respectively) and the placebo group (p < .001, p,01, p,01, respectively). Palpitations occurred only in the nifedipine group (p < .001). The day after the procedure, the headache was most prevalent in the nifedipine group compared to the naproxen group (p,001) and the placebo group (p,001). Conclusion: In our pilot study, pain relief and success rates for office diagnostic hysteroscopy were not significantly different between nifedipine, naproxen, and placebo. Nifedipine was associated with more, albeit tolerable, side-effects.
AB - Study Objective: To compare nifedipine, naproxen, or placebo for pain relief during diagnostic hysteroscopy. Design: Double-blind, randomized controlled pilot study. Setting: University hospital. Patients: Women scheduled for office diagnostic hysteroscopy (n = 60). Interventions: Women received nifedipine (2 tablets of 10 mg), naproxen (2 tablets of 250 mg), or placebo (2 tablets of 500 mg lactose) 30 to 60 minutes prior to hysteroscopy. Measurements and Main Results: Sixty patients were enrolled in the study (21 in the nifedipine group, 19 in the naproxen group, and 20 in the placebo group). The median pain scores during hysteroscope insertion, measured on a Visual Analog Scale (VAS), were 1 (interquartile range (IQR) 0–0), 2 (0–4) and 1 (0–1) in the nifedipine, naproxen and placebo group, respectively (P,14). The median VAS scores during hysteroscopy were 5 (IQR 2–7), 5 (4–8) and 5 (3–7) in the nifedipine, naproxen and placebo group, respectively (P,73). The median VAS scores immediately after hysteroscopy were 2 (IQR 0–4), 3 (0–6) and 3 (1–5) in the nifedipine, naproxen and placebo group, respectively (P,40). The median VAS scores 30 minutes after hysteroscopy were 1 (IQR 0–2), 1 (0–1) and 1 (0–2) in the nifedipine, naproxen and placebo group, respectively (P,63). Hysteroscope insertion failed in 1 case (naproxen group) because of cervica`l stenosis (P,32). Flushes, fatigue and vertigo, 30 minutes after the procedure, were significantly more prevalent in the nifedipine group compared to the naproxen (p < .001, p,03, p,03, respectively) and the placebo group (p < .001, p,01, p,01, respectively). Palpitations occurred only in the nifedipine group (p < .001). The day after the procedure, the headache was most prevalent in the nifedipine group compared to the naproxen group (p,001) and the placebo group (p,001). Conclusion: In our pilot study, pain relief and success rates for office diagnostic hysteroscopy were not significantly different between nifedipine, naproxen, and placebo. Nifedipine was associated with more, albeit tolerable, side-effects.
KW - Diagnostic hysteroscopy
KW - Efficacy
KW - Naproxen
KW - Nifedipine
KW - Office hysteroscopy
KW - Pain relief
UR - http://www.scopus.com/inward/record.url?scp=85150393174&partnerID=8YFLogxK
U2 - 10.1016/j.jmig.2023.02.010
DO - 10.1016/j.jmig.2023.02.010
M3 - Article
C2 - 36804576
AN - SCOPUS:85150393174
SN - 1553-4650
VL - 30
SP - 473
EP - 479
JO - Journal of Minimally Invasive Gynecology
JF - Journal of Minimally Invasive Gynecology
IS - 6
ER -